- Home
- UROY vs IVA Comparison
UROY vs IVA Comparison
Compare UROY & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- IVA
- Stock Information
- Founded
- UROY 2017
- IVA 2011
- Country
- UROY Canada
- IVA France
- Employees
- UROY N/A
- IVA N/A
- Industry
- UROY
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- IVA Health Care
- Exchange
- UROY Nasdaq
- IVA Nasdaq
- Market Cap
- UROY 336.8M
- IVA 359.6M
- IPO Year
- UROY N/A
- IVA 2020
- Fundamental
- Price
- UROY $2.62
- IVA $3.58
- Analyst Decision
- UROY Strong Buy
- IVA Strong Buy
- Analyst Count
- UROY 2
- IVA 4
- Target Price
- UROY $4.00
- IVA $10.50
- AVG Volume (30 Days)
- UROY 3.5M
- IVA 20.3K
- Earning Date
- UROY 08-19-2025
- IVA 09-24-2025
- Dividend Yield
- UROY N/A
- IVA N/A
- EPS Growth
- UROY N/A
- IVA N/A
- EPS
- UROY N/A
- IVA N/A
- Revenue
- UROY $11,285,840.00
- IVA $14,591,573.00
- Revenue This Year
- UROY $126.69
- IVA $44.22
- Revenue Next Year
- UROY N/A
- IVA $24.23
- P/E Ratio
- UROY N/A
- IVA N/A
- Revenue Growth
- UROY N/A
- IVA N/A
- 52 Week Low
- UROY $1.43
- IVA $1.53
- 52 Week High
- UROY $3.30
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- UROY 49.24
- IVA 59.00
- Support Level
- UROY $2.42
- IVA $3.16
- Resistance Level
- UROY $3.13
- IVA $3.58
- Average True Range (ATR)
- UROY 0.17
- IVA 0.30
- MACD
- UROY -0.04
- IVA 0.04
- Stochastic Oscillator
- UROY 22.86
- IVA 91.21
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.